Metered Dose Inhalers Market Size, Share, and Growth Forecast for 2025 - 2032

The global metered dose inhalers market size is anticipated to rise from US$ 30.3 Bn in 2025 to US$ 41 Bn by 2032. It is projected to witness a CAGR of 4.4% from 2025 to 2032.

A metered dosage inhalers are considered a significant respiratory device. Their ability to deliver a precise amount of medicine to the lungs via a brief burst of aerosolized medications is projected to boost demand.

• The National Health Technology Assessment Inhaler Review Group examined the clinical effectiveness of metered dosage inhalers and portable inhaler devices for drug delivery, finding them an affordable method for treating respiratory conditions like cystic fibrosis, COPD, and asthma.

Since metered dosage inhalers send a predetermined amount of medication to the lungs for pharmacological effect, their sales are rising worldwide. 

Key Highlights of the Metered Dose Inhalers Market

• Rising prevalence of respiratory diseases like asthma and COPD drives demand for metered-dose inhalers as primary treatment devices.
• The use of advanced valve designs and dose counters has enhanced medication delivery accuracy and patient compliance monitoring.
• The rise in regulatory changes favoring environmentally friendly propellants is driving innovation in inhaler formulations in North America.
• The focus on smart inhalers with digital connectivity is improving treatment monitoring and medication adherence tracking.
• The rise in healthcare spending and insurance coverage for respiratory medications is enhancing market accessibility in the Asia Pacific.

Growing Demand for Easy-to-use Inhalers Augmented Sales from 2019 to 2024

The global metered dose inhalers industry witnessed a CAGR of 3.5% in the historical period between 2019 and 2024. Compact aerosol dispensers with active medicinal components suspended in solvents or propellants are known as metered dosage inhalers. Due to their easy use in brief bursts of fixed dosage sprays, which the patient often administers herself, demand for these inhalers is rising.

• Novartis introduced Symbicort in 2018 to treat and prevent symptoms of asthma in adults and children aged 6 and above, as well as symptoms of chronic obstructive pulmonary disease (COPD), such as emphysema and chronic bronchitis.
• Diskus®, which is designed to prevent and manage symptoms including wheezing and shortness of breath, was introduced by Propeller Health in 2019.

Innovation in the Controlled Designs to Bolster Demand through 2032

In the estimated timeframe from 2025 to 2032, based on the studies by Persistence Market Research, the global market for metered dosage inhalers is likely to showcase a CAGR of 4.4%. with new and improved versions of clinically tested tools and drugs, industry players are envisioned to solidify their market presence in the healthcare infrastructure. For instance,

• In January 2023, Cipla Limited introduced Cippoint, a point-of-care testing tool that provides a variety of testing parameters for several illnesses, such as coagulation markers, diabetes, infectious diseases, thyroid function, inflammation, metabolic markers, thyroid function, and cardiac markers.

The device is a component in the development of combination therapy inhalers for complicated treatment demands and has CE IVD approval, which guarantees dependable testing solutions.  

Growth Drivers

Integration of Connected Devices to Spur Treatment Adherence in COPD and Asthma Management

The global MDI industry is expanding due to the rising use of connected devices in respiratory care and the adoption of digital health solutions. Smart inhalers, which integrate with mobile apps and cloud-based platforms, help track inhalation patterns, technique, and adherence rates.

Studies estimate that sales for smart inhalers were worth US$ 1.1 Bn in 2023 and are projected to expand as more people utilize digital solutions to treat their COPD and asthma. Medical device makers are anticipated to innovate with the designs of smart medical devices, that can cater the expanding patient pool across the globe. For instance,

• AstraZeneca unveiled a smart inhaler with real-time tracking in October 2023, while Propeller Health expanded digital asthma monitoring in November 2023 by partnering with GlaxoSmithKline.

Such advancements help patients better control their symptoms and allow doctors to tailor therapies for better respiratory care.

Rising Costs of Asthma Medications Limit Access to Treatment in Low and Middle-income Nations  

The high cost of medications and inhalers, little knowledge of cutting-edge therapies, and a decline in investment in research and development are the main obstacles facing the asthma treatment business. The market for metered dosage inhalers which are extensively used, is hard to increase because of their high production costs and possible adverse effects.

The industry reports that the cost of asthma medications rose by 8.5% in 2023, making them more expensive for patients in low- and middle-income nations. In these regions, industry players are anticipated to boost their production with innovative treatments and products that cater to the growing patient pool. For instance,

• AstraZeneca introduced Airsupra, a dual-action inhaler designed to lessen asthma episodes, in October 2023.
• Trelegy Ellipta, a triple-combination treatment for severe asthma, was extended by GSK in November 2023.

Improving accessibility and removing financial obstacles are essential for market expansion in the forthcoming decade.

Launch of Low-cost Generic Inhalers to Enhance Accessibility for Asthma Patients Worldwide

Increased investment in research and development, improvements in inhaler technology, and more reasonably priced drug alternatives may assist the metered dosage inhaler (MDI) industry expansion. The studies estimate that the worldwide asthma inhaler market was worth US$ 20.5 Bn in 2023 and is projected to grow due to new developments. For instance,

• Teva Pharmaceuticals launched a low-cost generic version of Symbicort in October 2023, making therapy more accessible.
• AstraZeneca introduced a next-generation smart inhaler with digital monitoring in November 2023 to improve asthma treatment.

Developing and upgrading MDI technology and pricing is crucial for greater treatment availability in light of the increased number of asthma sufferers.

Type Insights

Rising COPD Cases to Push Demand for Innovative Reliever Inhalers in the Market

The MDI market in 2025 is expected to be led by the reliever inhaler segment, accounting for 76% of the market share due to its rapid relief for acute respiratory symptoms. Short-acting beta-agonists (SABAs) like Ventolin by GSK and ProAir by Teva Pharmaceuticals continue to dominate prescriptions, especially for asthma patients requiring immediate bronchodilation.

The growing prevalence of asthma and chronic obstructive pulmonary disease (COPD) has fueled demand for quick-relief inhalers, with the World Health Organization estimating over 262 million asthma cases globally in 2023.

Meanwhile, the long-acting bronchodilator inhalers are set to grow significantly, capturing 24% of the market in 2025. Long-acting beta-agonists (LABAs) such as AstraZeneca’s Symbicort and Boehringer Ingelheim’s Spiriva are increasingly used for COPD management.

The FDA approved AstraZeneca’s Airsupra in January 2024, signaling increased investment in long-acting bronchodilators. With chronic respiratory diseases rising, the segment is set for sustained expansion in the upcoming years.

End User Insights

Rising Preference for Homecare to Spur Demand for User-friendly Metered Dose Inhalers

The homecare segment is projected to dominate the MDI market in 2025, holding a 58.4% share. The shift toward patient-centric and home-based care is driving the growth in demand, as managing asthma and chronic obstructive pulmonary disease at home offers cost savings, convenience, and better disease management.

The home-based respiratory care market expanded by 9.2% in 2023, reflecting increased adoption of at-home treatment solutions. Acknowledging such a trend, healthcare players are estimated to diversify their products to cater to homecare settings. For instance,

• Teva Pharmaceuticals introduced a user-friendly MDI for home use in November 2023, while Philips Respironics expanded its line of home-based inhaler solutions in October 2023, further boosting the homecare segment.

The hospital segment is expected to account for 32.1% of the market share in 2025, as severe respiratory conditions often require in-hospital treatment and specialized care.

On the other hand, clinics are projected to hold 9.5% of the market, providing outpatient services for patients with moderate respiratory issues. The rising preference for homecare solutions continues to drive MDI market expansion globally.

North America Sees Growth as Research and Innovation Address Rising Respiratory Diseases

North America is predicted to dominate the global metered dose market with a 34.9% share in 2025.

• According to the studies, the U.S., with a 36.8% market share, is the leading market for metered dose inhalers in North America, followed by Canada. From 2025 to 2032, the demand for MDIs in North America is estimated to record a CAGR of 4.7%.

The rise in respiratory diseases like asthma and COPD, coupled with an aging population, is driving market development in North America due to increased research, awareness of hi-tech respiratory devices, and respiratory disorders.

Improved Healthcare Infrastructure in Asia Pacific Shows Growth Aspects

Asia Pacific is set to hold a market share of 34% in the field of metered dose inhalers due to its large population, prevalence of respiratory ailments like COPD and asthma, emphasis on early diagnosis and treatment, and increased awareness of respiratory health. Asia Pacific is envisioned to report a CAGR of 7.3% from 2025 to 2032.

Improved healthcare infrastructure and economic growth in countries like China and India contribute to the availability of innovative respiratory therapies and medical facilities. Rising middle class in the region also accelerates the adoption of MDIs, and pharmaceutical companies are actively targeting Asia Pacific. For instance,

• The middle-class population is set to reach between 3.49 billion and 3.5 billion by 2030 in Asia Pacific.
• The number of middle-class households in Asia Pacific is projected to increase by about 352 million by 2034, totaling over a billion households and surpassing those in the U.S. by about eight times.

Patient-centric Care and Novel Inhaler Technologies to Shape Europe’s Growth Trajectory

In 2025, Europe's metered dose inhalers market is projected to capture 25.3% of the total share, with the U.K. and Germany emerging as key hubs in the region. Over the period from 2025 to 2032, Europe is anticipated to showcase a CAGR of 5.4%.

Growth can be largely attributed to a surging awareness of respiratory diseases, which has led to an increasing demand for effective treatment options in the pharmaceutical and healthcare industries. For example,

• In 2019, the median age-standardized prevalence rate (ASPR) for respiratory diseases in Europe was 3,230 per 100,000 males and 2,202 per 100,000 females.
• Respiratory diseases account for about 1 million deaths annually in the WHO European Region, with two-thirds of these occurring in the 28 countries of the European Union.

Europe's extensive patient population, combined with a growing trend toward integrating metered dose inhalers with other drug delivery systems, is likely to propel the market forward. The emphasis on innovative health solutions and patient-centric care will play a crucial role in shaping the future of the metered dose inhaler market in Europe.

To keep their market supremacy, leading companies in the metered dose inhalers industry employ strategic techniques including product launches, divestment, mergers and acquisitions, and collaborations. They make substantial investments in research and development to launch cutting-edge inhaler technology, emphasizing improved medication delivery, user-friendliness, and adherence.

AstraZeneca specializes in digital health solutions, whereas GlaxoSmithKline is known for its efficacious Ellipta inhaler. Additionally, they are striving to expand around the world, focusing on areas with untapped potential and the high prevalence of respiratory illnesses. With AstraZeneca raising its market position in emerging areas, Asia Pacific is also a sizable market. Leaders in the industry use innovation, worldwide market penetration, strategic partnerships, and portfolio diversity to obtain high share.

Key Industry Developments

• In November 2024, Bespak and Orbia Advance Corporation collaborated to develop climate-friendly inhalers using Zephex 152a propellant, aiming for global reformulation and commercialization of pMDI products.
• In November 2024, AptarGroup opened a new pharmaceutical facility in Taloja, India, to increase local manufacturing of innovations like pressurized metered dose inhaler valves and single-dose nasal sprays, and expand its presence in the Asia Pacific.
• In October 2024, Honeywell partnered with DevPro Biopharma to develop a low-emission respiratory inhaler, the Honeywell Solstice® Air HFO-1234ze, to reduce carbon emissions by 99.9%, with clinical trials set for 2025.
• In June 2024, Aseptika introduced PUFFClicker3, a universal smart inhaler dose tracker compatible with 101 SNOMED-coded inhalers, offering graphical instructions, a user-friendly design, and 16 languages for health inequities.